Abstract: backgROund: A single, effective therapeutic regimen for keloids has not been established yet, and the development of novel therapeutic approaches is expected. Butyrate, a short-chain fatty acid, and docosahexaenoic acid (DHA), a ω-3 polyunsaturated fatty acid, play multiple anti-inflammatory and anticancer roles via their respective mechanisms of action. Objective: In this study, we evaluated the antifibrogenic effects of their single and combined use on keloid fibroblasts. MethOds: Keloid fibroblasts were treated with butyrate (0-16 mM) and/or DHA (0-100 μM) for 48 or 96 h. Results: Butyrate inhibited cell proliferation, and α-smooth muscle actin (α-SMA) and type III collagen expressions, with inhibition of the transforming growth factor (TGF)-β1 and TGF-β type I receptor expressions and increased prostaglandin E2 with upregulation of cyclooxygenase-1 expression with induction of histone acetylation. DHA inhibited α-SMA, type III collagen, and TGF-β type I receptor expressions. Then, the butyrate/DHA combination augmented the antifibrogenic effects, resulting in additional inhibition of α-SMA, type I and III collagen expressions, with strong disruption of stress fiber and apoptosis induction. Moreover, the butyrate/DHA combination inhibited the cyclooxygenase-2 expression, suggesting stronger antiinflammatory effect than each monotherapy. study liMitatiOns: Activation in keloid tissue is affected not only by fibroblasts but also by epithelial cells and immune cells. Evaluation of the effects by butyrate and DHA in these cells or in an in vivo study is required. cOnclusiOn: This study demonstrated that butyrate and docosahexaenoic acid have antifibrogenic effects on keloid fibroblasts and that these may exert therapeutic effects for keloid. Keywords: Butyrates; Docosahexaenoic acids; Fibroblasts; Fibrosis; Keloid; Prostaglandins E An Bras Dermatol. 2017;92(2):184-90.
INTRODUCTION
Keloid and hypertrophic scars are dermal fibroproliferative disorders unique to humans, causing cosmetic deformities and psychological stress, which consequently impair the patient's quality of life. 1 Current treatment modalities such as surgery, radiation, and immunomodulation have been demonstrated to have therapeutic effects, but no modality has completely eliminated the risk of recurrence. 2, 3 Keloid formation has been linked to aberrant fibroblast activity resulting in increased expression of many potent cytokines and growth factors, especially transforming growth factor (TGF)-β1. 4 The binding of TGF-β1 to TGF-β receptors, including TGF-β type I receptor (TGF-βRI) and TGF-β type II receptor (TGF-βRII), leads to activation of the TGF-βRI by TGF-βRII-mediated phosphorylation. 5 As a result of the response to TGF-β1, cellular recruitment of the fibroblasts is enhanced, resulting in fibroblast differentiation into myofibroblasts; the differentiation causes intense cell proliferation, apoptosis resistance, and synthesis of extracellular matrix proteins, especially type I collagen (collagen I) and type III collagen (collagen III). 6 In fibroproliferative tissues, fibroblast differentiation into myofibroblasts is commonly identified by α-smooth muscle actin (α-SMA) expression, which is altered by stress fiber formation in the downstream signaling of TGF-β1. 7 Functionally, these cells can generate contractile force and promote fibrosis. Therefore, the suppression of these parameters may be useful in therapeutic approaches for keloids. In addition, keloid fibroblasts (KFBs) secrete less prostaglandin E 2 (PGE 2 ) than normal dermal fibroblasts (NFBs), 8 and PGE 2 has been reported to possess antifibrogenic activities such as inhibition of fibroblast proliferation, migration, and collagen expression in KFBs. 8, 9 Short-chain fatty acids (FAs) are the endproducts of anaerobic bacterial fermentation of dietary fibers in the colon. These FAs, predominantly butyrate and propionate, have a histone deacetylase (HDAC) inhibitor activity and play multiple roles such as apoptosis induction, proliferation regulation, and differentiation in the colonic epithelium. 10, 11 As for the effects of short-chain FAs on PGE 2 secre- production, and α-SMA expression through histone acetylation. [13] [14] [15] In our study using NFBs, butyrate exerted stronger antifibrogenic effects than propionate. 16 Moreover, butyrate was reported to be a more potent HDAC inhibitor than propionate. 10 However, these effects of butyrate on KFBs have not been investigated.
Docosahexaenoic acid (DHA) and eicosapentaenoic acid are major FAs in ω-3 polyunsaturated FAs of marine organisms, including fish oil. These FAs have anti-inflammatory and anticancer effects. 17, 18 Antifibrogenic effects of DHA have been reported in human peritoneal fibroblasts, including inhibition of TGF-β1, vascular endothelial growth factor, and collagen I expressions. 19 In our study using NFBs, DHA exerted stronger antifibrogenic effects than eicosapentaenoic acid, indicating inhibition of α-SMA, TGF-β1, and collagen III expressions, in concurrence with a report on human prostate carcinoma cell line. 16, 20 DHA is a ligand of peroxisome proliferator-activated receptor γ (PPARγ), and lipid mediators derived from DHA are potent agonists of PPARγ. 21 Many studies reported that PPARγ expression or activation inhibited collagen I, α-SMA, and TGF-βRI expressions in mouse skin and embryonic and human dermal fibroblasts. 21, 22 Therefore, PPARγ expression regulation by DHA might be a possible underlying mechanism of antifibrogenic effects. However, these effects of DHA on KFBs have not been investigated.
Although we have reported that butyrate and DHA showed inhibition of profibrotic factors in NFBs, the effect of these FAs in KFBs remain unclear. In the present study, we investigated the antifibrogenic effects of single and combined treatment with butyrate and DHA on KFBs by measuring profibrotic factors, cell proliferation, apoptosis, and stress fiber formation, and the underlying mechanism of the antifibrogenic effects on each FA by measuring PGE 2 secretion, histone acetylation, and PPARγ expression level.
METHODS

Primary keloid fibroblast cultures
KFBs were obtained from chest and earlobe keloid tissues of two Japanese patients. The protocol for tissue collection was approved by the ethics review board at Kobe University Graduate
School. Five or 6 pieces of the minced and deepithelialized samples were placed on a 100-mm tissue culture dish (Iwaki, Tokyo, Japan) and immersed in 2 mL Dulbecco's modified Eagle medium (DMEM;
Wako Pure Chemical Industries, Osaka, Japan) supplemented with 10% fetal bovine serum (FBS; Nichirei, Tokyo, Japan), penicillin (50 U/mL), and streptomycin (50 μg/mL; MP Biomedicals, Illkirch, France). On the following day, 15 mL of the medium was added to each dish. The culture medium was changed every 2 or 3 days until approximately 80% confluence was reached. The cells were passaged by incubation at 37°C with 0.05% trypsin and 0.02% EDTA, and plated in culture dishes.
Cell culture
KFBs were grown at a 37°C CO 2 incubator, using DMEM with 10% FBS. Only cells from passage 3 to 6 were used in this ex- 
FA treatment
Sodium butyrate (Sigma, St. Louis, MO) and sodium DHA (Sigma) were used. To evaluate the effects of the monotherapy, butyrate or DHA was applied at 0, 4, and 16 mM or 0 and 100 μM, respectively, after our experiments on NFBs. 16 To evaluate the combination treatment, butyrate was applied at 4 and 16 mM with DHA at 100 μM.
BrdU assays
KFBs were seeded into 96-well flat bottom plates and cultured in culture medium with 10% FBS. After 24 h, FAs were added and the cells were incubated for 48 h, followed by analysis using BrdU incorporation assay (Roche, Basel, Switzerland), according to the manufacturer's instructions.
RNA extraction, cDNA synthesis, and quantitative real-time polymerase chain reaction analysis
For the experiments, KFBs were seeded into each well of 6-well flat bottom plates and cultured in culture medium with 10%
FBS. After 24 h, FAs were added and the cells were incubated for 48 h. Then, the cells were processed for total RNA isolation using TRIzol (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions and reverse transcribed to yield a single-stranded cDNA, using iScript cDNA synthesis kits (Bio-Rad, Hercules, CA)
according to the manufacturer's instructions. The cDNAs were used for the subsequent quantitative real-time polymerase chain reaction (PCR) analysis, using SYBR Premix Ex Taq II (Takara Bio, Otsu, Japan) with each primer (Table 1) . 16, [23] [24] [25] [26] The PCR reactions were run on iCycler IQ (Bio-Rad, Hercules, CA) for 40 cycles at 95°C for 30 s, at an annealing temperature (Table 1) for 30 s, and at 72.0°C for 30 s.
Post-polymerase chain reaction melting curves were confirmed by the specificities of single-target amplification, and the relative expressions of each gene were calculated in duplicate based on glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression.
Western blotting
KFBs were seeded into each well of 6-well flat bottom plates and cultured in culture medium with 10% FBS. After 24 h, FAs were added and the plates were incubated for 48 h. After preparation of the KFBs in 1.5 mL tubes, they were suspended to 100 μL of ProPrep (iNtRON, Gyeonggi-do, Korea), according to the manufacturer's instructions. Five microliters of the cell supernatants was used to measure the protein concentration, using Lowry's method (RC DC Protein Assay Kit, Bio-Rad, Hercules, CA). Western blotting was performed as described previously, using primary antibodies against α-SMA (1:400; Sigma), acetyl-histone H3 (1:1000; Cell Signaling Technology Inc., Danvers, CO), PPARγ (1:800; Santa Cruz Biotechnology Inc., Santa Cruz, CA), GAPDH (1:40000; Sigma), and appropriate horseradish peroxidase-conjugated secondary antibody. 27 Densitometric results were analyzed using the Image J software (National Institutes of Health, Bethesda, MD). manufacturer's protocol, and an enzyme-linked immunosorbent assay reader (Benchmark Microplate Reader, Bio-Rad, Tokyo, Japan).
Measurement of PGE 2 levels in culture supernatants
Immunofluorescence staining
The morphological features of F-actin and the nuclei in KFBs were analyzed by immunofluorescence staining, as described previously, using phallotoxins (1:40; Invitrogen, Carlsbad, CA) and 4',6-diamidino-2-phenylindole (1:1000; Dojin, Kumamoto, Japan). 16 Immunofluorescent staining patterns were observed with a BX50 fluorescence microscope at ×200 magnification (Olympus, Tokyo, Japan) and recorded with a digital camera (EOS Kiss X4, Canon, Tokyo, Japan). Apoptotic cells were identified by nucleus condensation and fragmentation, and nuclei from 10 random fields of each coverslip were examined at ×100 magnification.
Statistical analysis
Data from independent experiments were used to calculate the mean ± SD values. Differences were considered significant if p < 0.05, as determined by the Tukey-Kramer post hoc test.
RESULTS
Profibrotic factor and TGF-β1 signal expressions
We evaluated the effects of butyrate and DHA on profibrotic factors in KFBs from chest. As for α-SMA expression, butyrate or DHA inhibited α-SMA mRNA expression similarly (p <0.01; Figure   1 
Alteration of histone acetylation and PPARγ expression in KFBs
Butyrate induced histone H3 acetylation dose-dependently To determine the mechanism of action of DHA, we also evaluated the PPARγ expression ( Figure 3) . Butyrate or DHA did not induce a significant PPARγ expression at 48 h of treatment.
F-Actin arrangement
Butyrate at 16 mM or DHA at 100 μM decreased stress fiber formation, with butyrate having a stronger effect than DHA (Figure 4) . The butyrate/DHA combination also strongly disrupted the stress fibers in the cytoplasm after 48 h of treatment.
PGE 2 synthesis
Butyrate increased PGE 2 secretion by 4.6-fold of the control at 16 mM (p <0.01; Figure 5 ), whereas DHA did not. inhibited cell proliferation; induced apoptosis; and strongly disrupted stress fibers. These findings suggest the therapeutic effect of the butyrate/DHA combination on the fibrogenesis of keloids.
The present finding of strong inhibition of cell proliferation without cell viability change by butyrate is in agreement with that of our previous report using NFBs and other reports using several normal fibroblasts. 16, 28, 29 This agreement suggests the efficacy of butyrate for not only normal fibroblasts but also activated fibroblasts in fibroproliferative disorders. KFBs were exposed for 48 h to the indicated concentrations of butyrate with 100 μM DHA. The protein expressions of (a) histone acetylation and (b) PPARγ were analyzed using western blotting. Results from a representative experiment are shown. Similar results were obtained from 6 independent experiments. The graphs show the histone acetylation/ GAPDH and PPARγ/GAPDH ratios. Data from 6 independent experiments were used to calculate the mean ± SD values (*p < 0.05 and **p < 0.01, vs. the control)
KFBs were exposed for 48 h to the indicated concentrations of butyrate with 100 μM DHA. (a) PGE2 concentrations in the medium were then measured. The mRNA expressions of (b) COX-1 and (c) COX-2 were analyzed by real-time polymerase chain reaction. Data from 6 independent experiments were used to calculate mean ± SD (*p < 0.05 and **p < 0.01, vs. the control; #p < 0.05 and ##p < 0.01, vs. DHA).
KFBs were exposed to DHA (100 μM), butyrate (16 mM The butyrate-induced histone acetylation is in agreement with a number of reports indicating antifibrogenic effects with the mechanism of cell cycle arrest at the G 1 /S phase and changes in a number of cell cycle regulatory gene expressions in rat embryonic fibroblasts. 13, 30, 31 Considering our results and those of the other reports, we suggest that the mechanism of the antiproliferative activity in KFBs could be due to the butyrate-induced histone acetylation.
Our result of DNA fragmentation after 96 h of treatment with butyrate coincides with the report using porcine fetal fibroblasts. 29 The stronger induction of apoptosis by the butyrate/DHA combination than that by monotherapy is in agreement with reports indicating the mechanism of synergistic induction of apoptosis in colonocytes. 32 From those reports, we suspect that the butyrate and DHA combination synergistically enhances apoptosis via an additional intrinsic mitochondrial pathway to a FAs-mediated extrinsic pathway reported to be activated in colonic cells by butyrate. 33 Further studies to elucidate this mechanism in KFBs are required.
The inhibition of collagen III and α-SMA expressions by butyrate or DHA is in agreement with our previous report on NFBs. In terms of TGF-β1 signaling, the inhibition of TGF-β1 and TGF-βRI mRNA expressions by butyrate indicates that butyrate could inhibit TGF-β1 signaling, followed by inhibitions in α-SMA and collagen expressions. Meanwhile, stress fiber disruption by butyrate as well as histone acetylation in the present study is in agreement with the report on human lung cell line demonstrating stress fiber disruption by histone acetylation using the phenylbutyrate-based HDAC inhibitor. 34 Furthermore, the inhibition of α-SMA expression accompanied with stress fiber disruption by butyrate in the present study is in agreement with our previous report on NFBs, and stress fiber formation is reported to upregulate α-SMA expression in fibroblasts. 16, 35 Therefore, stress fiber regulation would be one of the mechanisms in antifibrogenic effects by butyrate in addition to inhibition of TGF-β1 signaling.
DHA induced neither histone acetylation nor drastic stress fiber disruption, as observed in the butyrate treatment in this study.
Therefore, the mechanism of the antifibrogenic effects of DHA differs from that of butyrate. At first, we hypothesized that the anti- secretion in the present study could be due to increasing COX-1 expression by the butyrate-induced HDAC inhibitor activity. PGE 2 was reported to inhibit collagen synthesis and α-SMA in KFBs activated by TGF-β1 and fibroblasts of idiopathic pulmonary fibrosis. 38, 39 Therefore, we suggest that the increase in PGE 2 secretion by butyrate could be an underlying mechanism of profibrotic factor inhibition. Although the effect of the butyrate/DHA combination on PGE 2 secretion was similar to that of the butyrate monotherapy, the butyrate/DHA combination inhibited COX-2 expression, suggesting the importance to control inflammatory signaling in keloid tissues. 40 Considering this report, we suggest that an increase in PGE 2 secretion with downregulation of COX-2 expression could be beneficial for keloid therapies because of the anti-inflammatory and antifibrogenic effects. However, further studies to elucidate the anti-inflammatory effects of the butyrate/DHA combination are needed.
Activation in keloid tissue is affected not only by fibroblasts but also by epithelial cells and immune cells such as keratinocytes and neutrophils. 41 Therefore, evaluation of the effects of FAs on activated fibroblasts by cytokines, such as TGF-β1 and IL-1β, released from these cells is required to elucidate the effects on keloid tissues.
Similarly, evaluation of the butyrate/DHA combination in an in vivo study is also required; however, a human model of keloid has not been established yet.
CONCLUSIONS
We demonstrated the antifibrogenic effects of butyrate and DHA on KFBs. These findings could contribute to the development of novel therapy for dermal fibroproliferative disorders. q
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